Abstract Number: 2139 • 2018 ACR/ARHP Annual Meeting
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Background/Purpose: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Clinical hemolysis and severity…Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…Abstract Number: 2141 • 2018 ACR/ARHP Annual Meeting
Development of a Pediatric Glucocorticoid Toxicity Index
Background/Purpose: A Glucocorticoid Toxicity Index app (GTI 2.0) is now used as a clinical trial outcome measure in adults, but glucocorticoid (GC) toxicity issues in…Abstract Number: 2959 • 2018 ACR/ARHP Annual Meeting
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Background/Purpose: The U.S. Agency for Healthcare Research and Quality developed a set of general ambulatory care-sensitive conditions that may result acute care use (hospitalizations and…Abstract Number: 1190 • 2018 ACR/ARHP Annual Meeting
Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry
Background/Purpose: National registries of biologic drugs have proven to be valuable tools in following patients with rheumatic disease and some outcomes in real-life situations. The…Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting
Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…Abstract Number: 2253 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study
Background/Purpose: A recent US Medicaid study found that in addition to certain races (Asians and Blacks), older age, female sex, chronic kidney disease (CKD), and…Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…Abstract Number: 1263 • 2018 ACR/ARHP Annual Meeting
Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)
Background/Purpose: Combination therapy with DMARDs for treating RA is considered as standard of care. However, certain rates of adverse events (AEs) are unavoidable. The stigma…Abstract Number: 2339 • 2018 ACR/ARHP Annual Meeting
The Patient’s Perspective of Glucocorticoid Use: A Systematic Literature Review of Quantitative and Qualitative Studies
Background/Purpose: Glucocorticoids (GCs) remain widely used and have well documented adverse effects. However, the impact of these adverse effects from the perspective of the patient,…Abstract Number: 1398 • 2018 ACR/ARHP Annual Meeting
Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group
Background/Purpose: There is suboptimal reporting of adverse events (AE) in trials. The OMERACT Safety Working Group is developing a patient-centered AE collection and reporting approach…Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »